Education
About Us
Working with TipRanks
Follow Us
Orthocell Ltd (AU:OCC)
ASX:OCC
OCC Stock Chart & Stats
AU$0.90
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.90
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.86 - AU$1.70
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$242.82M
Enterprise ValueAU$190.01M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding271,307,950
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.33Price Target Upside47.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line expansion (19.57% year) indicates rising clinical adoption and demand for its regenerative products. Sustained revenue growth improves scale economics, supports incremental R&D and commercialization investment, and provides a pathway to durable margin recovery if cost control follows.
Low Leverage / Strong Capital StructureVery low debt-to-equity (0.04) and a healthy equity base give Orthocell conservative leverage and financial flexibility. This reduces refinancing and solvency risk, preserving capacity to fund clinical programs and manufacturing scale-ups without immediate interest or covenant pressures.
Specialized Regenerative Medicine Business ModelOrthocell’s focus on collagen implants and autologous cell therapies creates product-driven revenue streams tied to surgical and hospital channels. Specialization and the manufacturing/clinical delivery complexity establish higher operational barriers and durable differentiation versus commoditised device makers.
Bears Say
Persistent Negative ProfitabilityOngoing negative net profit and EBIT margins show the company has yet to convert revenue into sustainable profits. Persistent unprofitability limits internal reinvestment capacity, pressures returns on equity, and increases dependence on external funding to pursue growth and commercialization.
Negative Operating Cash FlowOperating cash flow is still negative even though free cash flow growth improved, indicating core operations consume cash. Persistent negative OCF strains liquidity, shortens runway for R&D and commercialization, and forces reliance on financing or dilution for durable funding.
Dependence On Regulatory, Reimbursement And ScaleCommercial success depends materially on regulatory approvals, reimbursement coverage and the ability to scale manufacturing and distribution. These structural dependencies carry execution and timing risk that can delay broad adoption and sustained revenue growth over multiple quarters.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.85 and its highest was AU$1.70 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$242.82M.
When is Orthocell Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Orthocell Ltd’s earnings last quarter?
Currently, no data Available
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 271,307,950 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.33 (47.78% Upside)
AU$1.33 (47.78% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$56.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-89.70%
Trailing 12-Months
Asset Growth
32.39%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.33
▲(47.78% Upside)
Technical Analysis
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---